Literature DB >> 35261811

Outcomes and recurrence patterns following curative hepatectomy for hepatocellular carcinoma patients with different China liver cancer staging.

Changxian Li1, Hongwei Wang1,2, Ruixiang Chen1, Hui Zhang1, Yonghua Xu2, Bin Zhang3, Yong Li4, Changhe Zhang5, Yue Yang6, Xuehao Wang1, Xiangcheng Li1.   

Abstract

This study aimed to investigate outcomes and recurrence patterns after hepatectomy for hepatocellular carcinoma (HCC) patients with different China Liver Cancer staging (CNLC), and then analyze the risk factors of different recurrence patterns. A total of 731 HCC patients undergoing curative resection were reviewed from 6 independent institutions. Data on preoperative and clinicopathological parameters, operation and tumor recurrence information, recurrence management and long-term outcomes were analyzed. Our results showed that 1-, 3-, and 5-year OS rate for Ia was 96.6%, 88.5%, and 77.4%, while 1-, 3-, and 5-year of Ib was 84.2%, 65.5%, and 51.3%, respectively. Compared to Ia, the patients in IIa and IIb staging had poorer 1-, 3-, and 5-year OS and DFS. Furthermore, the 1-, 3-, and 5-year OS rate in IIIa was 59.3%, 37.3%, and 27.7%, while the 1-, 3-, and 5-year OS of IIIb was 25.6%, 12.8%, and 0%, respectively. The mostly site of recurrence after liver surgery was intrahepatic recurrence (CNLC Ia: 89.4%; Ib: 65.9%; IIa: 68.9%; IIb: 91.7%; IIIa: 63.8%). However, the CNLC IIIb patients have higher percentage of extrahepatic recurrence (56.5%). The main recurrence pattern of time course was late recurrence in CNLC Ia patients (61.1%). However, the rate of early recurrence in Ib, IIa, IIb, IIIa, IIIb patients was 69.0%, 62.2%, 62.5%, 78.3% and 95.7% respectively. In conclusion, the outcomes and recurrence patterns of HCC patients after resection vary with different CNLC staging, which defined the prognosis of patients with HCC after resection. The HCC patients with CNLC IIIa can also benefit from liver resection. The CNLC staging could be considered in forming management strategies, treatment choice and surveillance for HCC patients. AJCR
Copyright © 2022.

Entities:  

Keywords:  CNLC staging; Hepatocellular carcinoma; OS; recurrence patterns; risk factors

Year:  2022        PMID: 35261811      PMCID: PMC8899998     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  34 in total

Review 1.  Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

Authors:  J-L Raoul; B Sangro; A Forner; V Mazzaferro; F Piscaglia; L Bolondi; R Lencioni
Journal:  Cancer Treat Rev       Date:  2010-08-17       Impact factor: 12.111

2.  Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification.

Authors:  Diamantis I Tsilimigras; Fabio Bagante; Kota Sahara; Dimitrios Moris; J Madison Hyer; Lu Wu; Francesca Ratti; Hugo P Marques; Olivier Soubrane; Anghela Z Paredes; Vincent Lam; George A Poultsides; Irinel Popescu; Sorin Alexandrescu; Guillaume Martel; Aklile Workneh; Alfredo Guglielmi; Tom Hugh; Luca Aldrighetti; Itaru Endo; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2019-07-02       Impact factor: 5.344

3.  Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy.

Authors:  Yusuke Yamamoto; Hisashi Ikoma; Ryo Morimura; Hirotaka Konishi; Yasutoshi Murayama; Shuhei Komatsu; Atsushi Shiozaki; Yoshiaki Kuriu; Takeshi Kubota; Masayoshi Nakanishi; Daisuke Ichikawa; Hitoshi Fujiwara; Kazuma Okamoto; Chouhei Sakakura; Toshiya Ochiai; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

Review 4.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Robin Kate Kelley; Augusto Villanueva; Amit G Singal; Eli Pikarsky; Sasan Roayaie; Riccardo Lencioni; Kazuhiko Koike; Jessica Zucman-Rossi; Richard S Finn
Journal:  Nat Rev Dis Primers       Date:  2021-01-21       Impact factor: 52.329

5.  Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria.

Authors:  Diamantis I Tsilimigras; Fabio Bagante; Dimitrios Moris; J Madison Hyer; Kota Sahara; Anghela Z Paredes; Rittal Mehta; Francesca Ratti; Hugo P Marques; Olivier Soubrane; Vincent Lam; George A Poultsides; Irinel Popescu; Sorin Alexandrescu; Guillaume Martel; Aklile Workneh; Alfredo Guglielmi; Tom Hugh; Luca Aldrighetti; Itaru Endo; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2020-04-13       Impact factor: 5.344

6.  Surgery for Recurrent Hepatocellular Carcinoma: Achieving Long-term Survival.

Authors:  Tomoaki Yoh; Satoru Seo; Kojiro Taura; Kohta Iguchi; Satoshi Ogiso; Ken Fukumitsu; Takamichi Ishii; Toshimi Kaido; Shinji Uemoto
Journal:  Ann Surg       Date:  2021-04-01       Impact factor: 12.969

7.  Prospective validation of the Barcelona Clinic Liver Cancer staging system.

Authors:  Umberto Cillo; Alessandro Vitale; Francesco Grigoletto; Fabio Farinati; Alberto Brolese; Giacomo Zanus; Daniele Neri; Patrizia Boccagni; Nela Srsen; Francesco D'Amico; Francesco Antonio Ciarleglio; Alessio Bridda; Davide Francesco D'Amico
Journal:  J Hepatol       Date:  2006-01-24       Impact factor: 25.083

8.  Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?

Authors:  Fabio Farinati; Dario Marino; Massimo De Giorgio; Anna Baldan; Maria Cantarini; Carmela Cursaro; Gianludovico Rapaccini; Paolo Del Poggio; Maria Anna Di Nolfo; Luisa Benvegnù; Marco Zoli; Franco Borzio; Mauro Bernardi; Franco Trevisani
Journal:  Am J Gastroenterol       Date:  2006-03       Impact factor: 10.864

9.  Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis.

Authors:  Parissa Tabrizian; Ghalib Jibara; Brian Shrager; Myron Schwartz; Sasan Roayaie
Journal:  Ann Surg       Date:  2015-05       Impact factor: 12.969

Review 10.  Hepatocellular carcinoma: clinical frontiers and perspectives.

Authors:  Jordi Bruix; Gregory J Gores; Vincenzo Mazzaferro
Journal:  Gut       Date:  2014-02-14       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.